Anzeige
Mehr »
Login
Dienstag, 21.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Aktienchance des Jahres! Ihre Chance auf explosive Gewinne!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0MR2G | ISIN: NO0010310956 | Ticker-Symbol: JEP
Tradegate
20.01.25
15:03 Uhr
47,900 Euro
-0,080
-0,17 %
1-Jahres-Chart
SALMAR ASA Chart 1 Jahr
5-Tage-Chart
SALMAR ASA 5-Tage-Chart
RealtimeGeldBriefZeit
47,86048,06020.01.
47,86048,08020.01.
GlobeNewswire (Europe)
1.107 Leser
Artikel bewerten:
(2)

SalMar ASA: SalMar - 2024 share-based incentive scheme for senior executives and key personnel

Finanznachrichten News

In accordance with the authorization granted by the AGM on 6 June 2024, the board of directors of SalMar ASA has decided to establish a share-based incentive scheme (Restricted Share Unit Plan) for senior executives and key personnel employed by the company and its subsidiaries. The scheme encompasses up to 300 000 shares and has a duration of three years. The company's liability with respect to the scheme will be met through existing holdings of treasury shares. As of 19 December 2024, SalMar ASA holds 114 554 treasury shares.

The purpose of the share-based incentive scheme (RSUP) is to encourage employees to maintain a deep, long-term engagement in the company, through a further alignment of the employees' interests with those of other shareholders. Under the RSUP, participating individuals will be awarded shares to motivate them to contribute to the continued success and profitability of the company, as well as deliver outstanding results. The RSUP will also enhance SalMar's ability to attract and retain staff.

Under the RSUP, participants will receive, free of charge, Restricted Share Units (RSUs), which, if certain predefined performance criteria are met within an accrual period, will be released and transferred to them as shares. The RSUP comprises three accrual periods of one, two and three calendar years respectively, with 2024 being the first year. Each accrual period encompasses 1/3 of the total number of RSUs included in the scheme. One RSU gives a contingent entitlement to one share.

The following criteria determine the award of RSUs during each of the three accrual periods:
- Award of 1/3 of the RSUs is independent of any performance criteria
- Award of 1/3 of the RSUs depends on SalMar achieving a certain EBIT/kg more than other aquaculture companies listed on the Oslo Stock Exchange during the accrual period
- Award of 1/3 of the RSUs depends on SalMar's shares achieving a higher total shareholder return (TSR) than a defined group of comparable companies during the accrual period.

Accrual of RSUs under the scheme presumes that the individual is an employee of SalMar or a participating subsidiary. The total gain from released RSUs during one calendar year shall not exceed 100 per cent of the participant's basic salary. Under the scheme's rules, the number of RSUs will be adjusted in the event of a dividend payout in order to preserve, but not increase, the value of the RSU allocation.

The RSUP goes into effect on 19 December 2024 and encompasses senior executives and key personnel at SalMar and its subsidiaries.

Restricted share units granted primary insiders 19 December 2024:

Frode Arntsen has received 4 190 RSUs in the Company
Roger Bekken has received 2 984 RSUs in the Company
Eva Haugen has received 1 443 RSUs in the Company
Håkon Husby has received 1 082 RSUs in the Company
Ingvild Kindlihagen has received 498 RSUs in the Company
Runar Sivertsen has received 2 094 RSUs in the Company
Ulrik Steinvik has received 2 406 RSUs in the Company
Arthur Wisniewski has received 1 732 RSUs in the Company
Simon Søbstad has received 2 308 RSUs in the Company

New holdings:

After completion of the abovementioned grant Frode Arntsen holds 9 377 RSUs in the Company. As of today the primary insider holds 9 324 shares in the Company.

After completion of the abovementioned grant Roger Bekken* holds 6 583 RSUs in the Company. As of today the primary insider holds 16 259 shares in the Company.

After completion of the abovementioned grant Eva Haugen holds 3 186 RSUs in the Company. As of today the primary insider holds 884 shares in the Company.

After completion of the abovementioned grant Håkon Husby holds 2 381 RSUs in the Company. As of today the primary insider holds 2 190 shares in the Company.

After completion of the abovementioned grant Ingvild Kindlihagen holds 1 095 RSUs in the Company. As of today the primary insider holds 276 shares in the Company.

After completion of the abovementioned grant Runar Sivertsen** holds 4 182 RSUs in the Company. As of today the primary insider holds 5 959 shares in the Company.

After completion of the abovementioned grant Ulrik Steinvik*** holds 5 311 RSUs in the Company. As of today the primary insider holds 121 855 shares in the Company.

After completion of the abovementioned grant Arthur Wisniewski holds 3 820 RSUs in the Company. As of today the primary insider holds 3 776 shares in the Company.

After completion of the abovementioned grant Simon Søbstad holds 4 742 RSUs in the Company. As of today the primary insider holds 1 737 shares in the Company.

* Owns 16 259 shares directly and indirectly through personal relative.

** Owns 5 959 shares directly and indirectly through personal relative.

*** Owns 121 855 shares directly and indirectly through personal related parties. Also owns 100 per cent of the shares in Nordpilan AS. Nordpilan AS owns 0.17 per cent of the shares in Kverva AS, which in turn through Kverva Industrier AS owns 45.4 per cent of the shares in SalMar ASA.

For more information, please contact:
Håkon Husby, Head of Investor Relations
Phone: + 47 936 30 449
E-mail: hakon.husby@salmar.no
Website: www.salmar.no

This information is subject to the disclosure requirements pursuant to Article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.